Related references
Note: Only part of the references are listed.Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
Hong Zhao et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study
Jose Luis Rodriguez-Garcia et al.
RHEUMATOLOGY (2021)
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
Shruti Gupta et al.
JAMA INTERNAL MEDICINE (2021)
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial
Olivier Hermine et al.
JAMA INTERNAL MEDICINE (2021)
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial
Carlo Salvarani et al.
JAMA INTERNAL MEDICINE (2021)
Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia
Jonathan B. Parr
JAMA INTERNAL MEDICINE (2021)
Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial
Payam Tabarsi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Carlos Salama et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
Viviane C. Veiga et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
Xavier Mariette et al.
LANCET RESPIRATORY MEDICINE (2021)
HHS Funds Development of Antibiotic to Treat Anthrax
Rita Rubin
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Yang Cao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Personal respirators for population level control of the COVIDI9 pandemic
Paul Elkington et al.
JOURNAL OF INFECTION (2020)
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
Wei Tang et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial
Caleb P. Skipper et al.
ANNALS OF INTERNAL MEDICINE (2020)
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Emanuel Della-Torre et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
Dennis McGonagle et al.
AUTOIMMUNITY REVIEWS (2020)
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study
Valentina Giudice et al.
FRONTIERS IN PHARMACOLOGY (2020)
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial
Ke Hu et al.
VIROLOGICA SINICA (2020)
Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19)
Pierre Francois Laterre et al.
JAMA NETWORK OPEN (2020)
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial
Spyridon G. Deftereos et al.
JAMA NETWORK OPEN (2020)
Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19
Wioleta M. Zelek et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
被撤回的出版物: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study (Retracted article. See vol. 107, pg. 728, 2022)
Sherief Abd-Elsalam et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)
Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
Adrian V. Hernandez et al.
ANNALS OF INTERNAL MEDICINE (2020)
A minimal common outcome measure set for COVID-19 clinical research
J. C. Marshall et al.
LANCET INFECTIOUS DISEASES (2020)
Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study
Bo Wang et al.
BMC INFECTIOUS DISEASES (2020)
The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial
Naser Gharebaghi et al.
BMC INFECTIOUS DISEASES (2020)
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
Maryam Edalatifard et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial
Pierre-Francois Dequin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial
Bruno M. Tomazini et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
Zelalem Temesgen et al.
MAYO CLINIC PROCEEDINGS (2020)
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Peter Horby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
Magnus Nakrem Lyngbakken et al.
NATURE COMMUNICATIONS (2020)
Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2020)
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Anup Agarwal et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome
Massimo Caracciolo et al.
FRONTIERS IN IMMUNOLOGY (2020)
Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients
Robert J. Ulrich et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19 A Randomized Clinical Trial
Wesley H. Self et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)
Cheng-Pin Chen et al.
PLOS ONE (2020)
An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19
Weihui Fu et al.
ECLINICALMEDICINE (2020)
Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab
Armando Caballero et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)
Baricitinib restrains the immune dysregulation in patients with severe COVID-19
Vincenzo Bronte et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Alexander P. J. Vlaar et al.
LANCET RHEUMATOLOGY (2020)
Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis
Carlos K. H. Wong et al.
SCIENTIFIC REPORTS (2020)
Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial
Hamid Rahmani et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study
Djillali Annane et al.
ECLINICALMEDICINE (2020)
Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study
Henry D. Huang et al.
CARDIOLOGY AND THERAPY (2020)
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
Giacomo De Luca et al.
LANCET RHEUMATOLOGY (2020)
Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin
Alessia Alunno et al.
RMD OPEN (2020)
Canakinumab in a subgroup of patients with COVID-19
Claudio Ucciferri et al.
LANCET RHEUMATOLOGY (2020)
Share Paper
